GLPwatch
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.
Front Med · 2022
Last updated 2026-05-28Semaglutide is a GLP-1 drug that helps control blood sugar in people with type 2 diabetes by increasing insulin and reducing glucagon. It also slows stomach emptying and reduces appetite, which can lead to weight loss. Clinical evidence shows its effects on both diabetes and obesity, though no drug is considered perfect for obesity treatment.
AI summary of the abstract below.
| Journal | Front Med, 2022 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 0.60 |
| NIH percentile | 34 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
Verbatim abstract via PubMed 35226299 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.